• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Valeant Pharmaceuticals International

Valeant Pharmaceuticals International

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Hedge Funds Bet Against Australia's Big Banks in Record Numbers

    Hedge Funds Bet Against Australia's Big Banks in Record Numbers

  2. SEC Reviewed Valeant's Use of 'Non-GAAP' Financial Measures -- Update

    SEC Reviewed Valeant's Use of 'Non-GAAP' Financial Measures -- Update

  3. Valeant Investor Sequoia Fund to Limit Stakes in a Single Stock

    Valeant Investor Sequoia Fund to Limit Stakes in a Single Stock

  4. Valeant Investor Sequoia Fund to Limit Stakes in a Single Stock

    Valeant Investor Sequoia Fund to Limit Stakes in a Single Stock

  5. Paulson & Co. sheds healthcare stocks, picks up some tech

    Paulson & Co. sheds healthcare stocks, picks up some tech

  6. Painful Valeant Debacle Spurs Improvements at Sequoia

    Sequoia shareholders meeting highlights structural changes in investment policy, risk management, and decision-making.

  7. Perrigo Updates First-Quarter Loss Figure to Reflect Lower Tax Benefit

    Perrigo Updates First-Quarter Loss Figure to Reflect Lower Tax Benefit

  8. 'We are on the brink of a catastrophe': 9 highlights from Bill Ackman's Valeant emails

    'We are on the brink of a catastrophe': 9 highlights from Bill Ackman's Valeant emails

  9. Valeant on track to beat earnings deadline, company says

    Valeant on track to beat earnings deadline, company says

  10. Retinal Vein Occlusion Global Clinical Trials Review 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Bayer, Pfizer, Novartis - Research and Markets

    Retinal Vein Occlusion Global Clinical Trials Review 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Bayer, Pfizer, Novartis - Research and Markets

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.